DRTSW (Alpha Tau Medical) Debt-to-Asset : 0.15 (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Alpha Tau Medical Debt-to-Asset?

Alpha Tau Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $1.00 Mil. Alpha Tau Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $11.29 Mil. Alpha Tau Medical's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was $80.93 Mil. Alpha Tau Medical's debt to asset for the quarter that ended in Mar. 2025 was 0.15.

Alpha Tau Medical Debt-to-Asset Historical Data

The historical data trend for Alpha Tau Medical's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Tau Medical Debt-to-Asset Chart

Alpha Tau Medical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.12

0.15

Alpha Tau Medical Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial														0.13	0.13	0.14	0.15	0.15

Competitive Comparison of Alpha Tau Medical's Debt-to-Asset

For the Biotechnology subindustry, Alpha Tau Medical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpha Tau Medical's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Alpha Tau Medical's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Alpha Tau Medical Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Alpha Tau Medical's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.011	+	11.525)	/	86.204
	=	0.15

Alpha Tau Medical's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.001	+	11.292)	/	80.928
	=	0.15

Alpha Tau Medical (NAS:DRTSW) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Alpha Tau Medical Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Alpha Tau Medical's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpha Tau Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Tau Medical Ltd (NAS:DRTSW) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

DRTS:USA

Address

Kiryat Hamada Street 5, Jerusalem, ISR, 9777605

Website

https://www.alphatau.com

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.